Evidence map›Paper›PMID 36232758›Full record

ArticleInternational journal of molecular sciences2022

Measurement of Hepatic CYP3A4 and 2D6 Activity Using Radioiodine-Labeled

Asuka Mizutani, Masato Kobayashi, Riku Aibe, Yuka Muranaka, Kodai Nishi, Masanori Kitamura, Chie Suzuki, Ryuichi Nishii, Naoto Shikano, Yasuhiro Magata and 3 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.4field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 7 institutions in 1 country.

Asuka MizutaniFaculty of Health Sciences, Institute of Medical, Pharmaceutical and Health Sciences, Kanazawa University, 5-11-80 Kodatsuno, Kanazawa 920-0942, Ishikawa, Japan.
Masato KobayashiFaculty of Health Sciences, Institute of Medical, Pharmaceutical and Health Sciences, Kanazawa University, 5-11-80 Kodatsuno, Kanazawa 920-0942, Ishikawa, Japan.ORCID 0000-0001-5172-2626
Riku AibeDivision of Health Sciences, Graduate School of Medical Sciences, Kanazawa University, 5-11-80 Kodatsuno, Kanazawa 920-0942, Ishikawa, Japan.
Yuka MuranakaDivision of Health Sciences, Graduate School of Medical Sciences, Kanazawa University, 5-11-80 Kodatsuno, Kanazawa 920-0942, Ishikawa, Japan.
Kodai NishiDepartment of Radioisotope Medicine, Atomic Bomb Disease Institute, Nagasaki University, 1-12-4 Sakamoto, Nagasaki 852-8523, Nagasaki, Japan.ORCID 0000-0002-4919-7639
Masanori KitamuraFaculty of Pharmaceutical Sciences, Matsuyama University, 4-2 Bunkyo-cho, Matsuyama 790-8578, Ehime, Japan.ORCID 0000-0002-8087-1855
Chie SuzukiPreeminent Medical Photonics Education & Research Center, Hamamatsu University School of Medicine, 1-20-1 Handayama, Higashi, Hamamatsu 431-3192, Shizuoka, Japan.
Ryuichi NishiiDepartment of Molecular Imaging and Theranostics, Institute for Quantum Medical Science, Quantum Life and Medical Science Directorate, National Institutes for Quantum and Radiological Science and Technology, 4-9-1 Anagawa, Inage, Chiba 263-8555, Chiba, Japan.ORCID 0000-0002-2096-4611
Naoto ShikanoDepartment of Radiological Sciences, Ibaraki Prefectural University of Health Sciences, 4669-2 Ami, Inashiki 300-0394, Ibaraki, Japan.
Yasuhiro MagataPreeminent Medical Photonics Education & Research Center, Hamamatsu University School of Medicine, 1-20-1 Handayama, Higashi, Hamamatsu 431-3192, Shizuoka, Japan.
Yasushi IshidaDepartment of Psychiatry, Faculty of Medicine, University of Miyazaki, 5200 Kihara, Kiyotake, Miyazaki 889-1692, Miyazaki, Japan.ORCID 0000-0002-7601-4906
Munetaka KunishimaFaculty of Pharmaceutical Sciences, Institute of Medical, Pharmaceutical and Health Sciences, Kanazawa University, Kakuma, Kanazawa 920-1192, Ishikawa, Japan.
Keiichi KawaiFaculty of Health Sciences, Institute of Medical, Pharmaceutical and Health Sciences, Kanazawa University, 5-11-80 Kodatsuno, Kanazawa 920-0942, Ishikawa, Japan.
Kanazawa University · JPHamamatsu University School of Medicine · JPIbaraki Prefectural University of Health Sciences · JPMatsuyama University · JPNagasaki University · JPNational Institutes for Quantum Science and Technology · JPUniversity of Miyazaki · JP

Funding

Grants-in-Aid for Scientific Research from the Japan Society for the Promotion of Science 18K19508 and 19K17194
6 · The paper itself

Abstract

Drug metabolizing enzyme activity is affected by various factors such as drug-drug interactions, and a method to quantify drug metabolizing enzyme activity in real time is needed. In this study, we developed a novel radiopharmaceutical for quantitative imaging to estimate hepatic CYP3A4 and CYP2D6 activity. Iodine-123- and 125-labeled

Indexed as

Cytochrome P-450 CYP2D6Cytochrome P-450 CYP3AIodine RadioisotopesLiverAnimalsDesvenlafaxine SuccinateMiceRadiopharmaceuticalsVenlafaxine Hydrochloridecytochrome P450 3A4, mouseCytochrome P-450 CYP2D6Cytochrome P-450 CYP3ADesvenlafaxine SuccinateIodine-123Iodine-125Iodine RadioisotopesRadiopharmaceuticalsVenlafaxine HydrochlorideCYP2D6CYP3A4individualized medicineO-desmethylvenlafaxinewhole-body imaging

Identifiers

PMID36232758
PMCPMC9569593
OpenAlexW4297477328

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.